Development of a measles vaccine production process in MRC-5 cells grown on Cytodex1 microcarriers and in a stirred bioreactor

Applied Microbiology and Biotechnology

Volumn 93, Issue 3, 2012, Pages 1031-1040

  Trabelsi, Khaled ^a   Majoul, Samy ^a   Rourou, Samia ^a   Kallel, Héla ^a  

^a PASTEUR INSTITUTE OF TUNIS   (Tunisia)

Author keywords

AIK C measles strain; Cytodex 1 microcarriers; Measles vaccine; MRC 5 cells; Stirred bioreactor

Indexed keywords

CELL AMPLIFICATION; CHARGED IONS; GLUCOSE REGULATION; HIGH CELL DENSITY; INFECTIOUS VIRUS; MEASLES VIRUS; MICROCARRIERS; MULTIPLICITY OF INFECTIONS; OPERATIONAL PARAMETERS; PHOSPHATE-BUFFERED SALINES; PROCESS SCALE-UP; PRODUCTION PROCESS; REACTOR VOLUME; REPEATED-BATCH CULTURE; SPECIFIC PRODUCTIVITY; SPINNER FLASKS; STIRRED BIOREACTORS; SUSPENSION CULTURES; VACCINE PRODUCTION; VIRUS REPLICATION;

AMINO ACIDS; BATCH CELL CULTURE; BIOCONVERSION; BIOREACTORS; BOTTLES; CELL GROWTH; GLUCOSE; OPTIMIZATION; PRODUCTION ENGINEERING; SUGAR (SUCROSE); TISSUE; TISSUE CULTURE; VACCINES; VIRUSES;

CELLS;

ALANINE; AMINO ACID; ARGININE; HISTIDINE; ION; LACTOSE; MAGNESIUM CHLORIDE; MEASLES VACCINE; METHIONINE; PHOSPHATE BUFFERED SALINE; SORBITOL; SUCROSE;

AMINO ACID; BIOREACTOR; DRUG; GLUCOSE; INFECTIVITY; MEASLES; OPTIMIZATION; VACCINATION; VACCINE; VIRUS;

ANIMAL CELL; ARTICLE; CELL COUNT; CELL CYCLE PHASE; CELL DENSITY; CELL EXPANSION; CELL GROWTH; CONCENTRATION RESPONSE; CULTURE MEDIUM; CULTURE OPTIMIZATION; DRUG STABILITY; FED BATCH CULTURE; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MEASLES VACCINATION; MEASLES VIRUS; MICROCARRIER CULTURE; NONHUMAN; PERFUSION; PH; POROSITY; STIRRED REACTOR; STORAGE TEMPERATURE; SURFACE CHARGE; SUSPENSION CELL CULTURE; VACCINE PRODUCTION; VIRUS INFECTIVITY; VIRUS REPLICATION;

BIOREACTORS; BIOTECHNOLOGY; CELL CULTURE TECHNIQUES; CELL LINE; CULTURE MEDIA; DEXTRANS; FIBROBLASTS; HUMANS; MEASLES VACCINE; MEASLES VIRUS; MICROSPHERES; VIRUS CULTIVATION; VIRUS REPLICATION;

MEASLES VIRUS;

EID: 84856375070     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-011-3574-y     Document Type: Article

References (31)

1. Audsley JM, Tannock GA (2005) The growth of attenuated influenza vaccine donor strains in continuous cell lines. J Virol Methods 2:187-193 (Pubitemid 40037796)
2. Aunins JG, Bader B, Caola A, Griffiths J, Katz M, Licari P, Ram K, Ranucci CS, Zhou W (2003) Fluid mechanisms, cell distribution and environment in cellcube bioreactors. Biotechnol Prog 19:2-8 (Pubitemid 36219297)
3. Aunins JG (2000) Viral vaccine production in cell culture. In: Spier ER (ed) Encyclopedia of cell technology. Wiley, New York, pp 1183-1207
4. Bautista-Lopez N, Ward BJ, Mills E, McCornick D, Martel N, Ratnam S (2000) Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination. Vaccine 18:1393-1401 (Pubitemid 30017852)
5. Brandau DT, Jones LS, Wiethoff CM, Rexroad J, Middaugh CR (2003) Thermal stability of vaccines. J Pharm Sci 92:218-231 (Pubitemid 36169294)
6. Butler M (1987) Growth limitations on microcarriers. Adv Biochem Eng Biotechnol 34:57-84
7. Cutts FT, Clements CJ, Bennett JV (1997) Alternative routes of measles immunization: a review. Biologicals 25:323-338 (Pubitemid 27453255)
8. Erk I, Huet J, Duarte M, Duquerroy S, Rey F, Cohen J, Lepault J (2003) A zinc ion controls assembly and stability of the major capsid protein of rotavirus. J Virol 6:3535-3601
9. Genzel Y, Fischer M, Reichl U (2006) Serum-free influenza virus production avoiding washing steps and medium exchange in large-scale microcarrier culture. Vaccine 24:3261-3272
10. Griffin DE, Pan CH (2009) Measles: old vaccines, new vaccines. In: Griffin DE, Oldstone MBA (eds) Measles-Pathogenesis and control. Springer, Berlin, pp 191-212
11. Griffin DE, Bellini WJ (2001) Measles virus. In: Knipe DM, Howley PM (eds) Fields virology, 4th edn. Lippincott Williams & Wilkins, Philadelphia, pp 1267-1312
12. Griffin DE (1995) Immune response during measles virus infection. Curr Trop Microbiol Immunol 191:117-134
13. Lang J, Cetre JC, Picot N, Lanta M, Briantais P, Vital S, Le Mener V, Lutsch C, Rotivel Y (1998) Immunogenicity and safety in adults of a new chromatographically purified Vero-cell rabies vaccine (CPRV): a randomized, double-blind trial with purified Vero-cell rabies vaccine (PVRV). Biologicals 4:299-308 (Pubitemid 29263789)
14. Kissman J, Salvador FA, Rudolph A, Braun C, Cape SP, Sievers RE, Federspiel MJ, Joshi SB, Middaugh CR (2008) Stabilization of measles virus for vaccine formulation. Hum Vaccines 4:350-359
15. Kuno-Sakai H, Kimura M (2003) Removal of gelatin from live vaccines and DTaP-an ultimate solution for vaccine-related gelatin allergy. Biologicals 4:245-249 (Pubitemid 37414919)
16. Maranga L, Brazão TF, Carrondo MJ (2003) Virus-like particle production at low multiplicities of infection with the baculovirus insect cell system. Biotechnol Bioeng 2:245-253 (Pubitemid 37176337)
17. Moss WJ, Griffin DE (2006) Global measles elimination. Nat Rev Microbiol 12:900-908 (Pubitemid 44768252)
18. Montagnon B, Vincent-Falquet JC, Fanget B (1984) Thousand liter scale microcarrier culture of Vero cells for killed polio virus vaccine. Dev Biol Stand 55:37-42 (Pubitemid 14102764)
19. Nechaeva EA, Kashentseva EA, Agafonov AP, Varaksin NA, Ryabicheva TG, Konstantinov AP, Bondarenko VN, Kolokoltsova TD, Kits IV, Senkina TY, Zhilina NV (1998) New form of the live measles vaccine for oral administration. In: Merten OW, Perrin P, Griffiths B (eds) New developments and new applications in animal cell technology. Kluwer Academic Publishing, Dordrecht, pp 573-575
20. Nkrumah FK, Osei-Kwasi M, Dunyo SK, Koram KA, Afari EA (1998) Comparison of AIK-C measles vaccine in infants at 6 months with Schwarz vaccine at 9 months: a randomized controlled trial in Ghana. WHO Bull 76:353-359 (Pubitemid 28469268)
21. Ohtake S, Martin RA, Yee L, Chen D, Kristensen DD (2010) Heat stable measles vaccine produced by spray drying. Vaccine 28:1275-1284
22. Radlett PJ (1987) The use of BHK suspension cells for the production of foot and mouth disease vaccines. Adv Biochem Eng Biotechnol 34:129-146
23. Shirley JA, Beards GM, Thouless ME, Flewett TH (1981) The influence of divalent cations on the stability of human rotavirus. Arch Virol 1:1-9 (Pubitemid 11178239)
24. Sidorenko ES, Dorofeeva LV, Kaptsova TI, Steinberg LL, Zasorina IN, Sinitsyna OA, Boriskin YS (1989) Experimental-scale measles and mumps vaccine production on microcarrier-grown cells. Vaccine 7:554-556 (Pubitemid 20064270)
25. Tidjani O, Grunitsky B, Guerin N, Levy-Bruhk D, Lecam N, Xuereff C, Tatagen K (1989) Serological effects of Edmonston-Zagreb, Schwarz and AIK-C measles vaccine strains given at ages 4-5 or 8-10 months. Lancet 2:1357-1360 (Pubitemid 20002967)
26. Turnbull AE, Skulimowski A, Smythe JA, Alexander IE (2000) Adenoassociated virus vectors show variable dependence on divalent cations for thermostability: implications for purification and handling. Hum Gene Therapy 4:629-635 (Pubitemid 30134306)
27. Trabelsi K, Rourou S, Loukil H, Majoul S, Kallel H (2006) Optimization of virus yield as a strategy to improve rabies vaccine production by Vero cells in a bioreactor. J Biotechnol 121:261-271 (Pubitemid 43038574)
28. Trabelsi K, Rourou S, Loukil H, Majoul S, Kallel H (2005) Comparison of various culture modes for the production of rabies virus by Vero cells grown on microcarriers in a 2-l bioreactor. Enzyme Microb Biotechnol 36:514-519 (Pubitemid 40186849)
29. Tree JA, Richardson C, Fooks AR, Clegg JC, Looby D (2001) Comparison of large-scale mammalian cell culture systems with egg culture for the production of influenza virus A vaccine strains. Vaccine 25-26:3444-3450 (Pubitemid 32710294)
30. Warnock JN, Al-Rubeai M (2006) Bioreactor systems for the production of biopharmaceuticals from animal cells. Biotechnol Appl Biochem 45:1-12 (Pubitemid 44032553)
31. Wolfson LJ, Strebel PM, Gacic-Dobo M, Hockstra EJ, McFarland JW, Hersh BS (2007) Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. Lancet 369:191-200 (Pubitemid 46107682)